Entry Point Capital, LLC Roivant Sciences Ltd. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Entry Point Capital, LLC holds 53,443 shares of ROIV stock, worth $564,358. This represents 0.29% of its overall portfolio holdings.
Number of Shares
53,443
Previous 12,479
328.26%
Holding current value
$564,358
Previous $144,000
338.89%
% of portfolio
0.29%
Previous 0.08%
Shares
4 transactions
Others Institutions Holding ROIV
# of Institutions
338Shares Held
511MCall Options Held
813KPut Options Held
1.01M-
Qvt Financial LP New York, NY65.8MShares$695 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$655 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$505 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$466 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$374 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.44B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...